Unity Biotechnology's Total Assets for the quarter that ended in Dec. 2023 was $65.69 Mil.
During the past 12 months, Unity Biotechnology's average Total Assets Growth Rate was -23.90% per year.
During the past 3 years, the average Total Assets Growth Rate was -27.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 12.50% per year.
During the past 8 years, Unity Biotechnology's highest 3-Year average Total Assets Growth Rate was 55.80%. The lowest was -27.30%. And the median was 47.70%.
Total Assets is connected with ROA %. Unity Biotechnology's annualizedROA % for the quarter that ended in Dec. 2023 was -8.88%. Total Assets is also linked to Revenue through Asset Turnover. Unity Biotechnology's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Unity Biotechnology Total Assets Historical Data
The historical data trend for Unity Biotechnology's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Unity Biotechnology Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
151.22
156.32
124.71
124.35
65.69
Unity Biotechnology Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
124.35
114.26
101.01
69.27
65.69
Unity Biotechnology Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Unity Biotechnology's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unity Biotechnology (NAS:UBX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Unity Biotechnology's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Unity Biotechnology Total Assets Related Terms
Thank you for viewing the detailed overview of Unity Biotechnology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Unity Biotechnology (Unity Biotechnology) Business Description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UBX has been successfully added to your 